Perrigo Beheer
Beheer criteriumcontroles 1/4
De CEO Perrigo is Patrick Lockwood-Taylor, benoemd in Jun2023, heeft een ambtstermijn van 2.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.04M, bestaande uit 13.5% salaris en 86.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.08% van de aandelen van het bedrijf, ter waarde $ 1.24M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 5.4 jaar.
Belangrijke informatie
Patrick Lockwood-Taylor
Algemeen directeur
US$9.0m
Totale compensatie
| Percentage CEO-salaris | 13.53% |
| Dienstverband CEO | 2.9yrs |
| Eigendom CEO | 0.08% |
| Management gemiddelde ambtstermijn | 1.8yrs |
| Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
Narratiefupdate • May 09
PRGO: Future Upside Will Hinge On Infant Nutrition Turnaround
Analysts have trimmed the Perrigo price target to $16.50 from $17. This reflects updated views on modest revenue growth potential, slightly lower profit margins, and a higher assumed future P/E multiple, while keeping the discount rate essentially unchanged.Seeking Alpha • Apr 28
Perrigo: Positioning Through A Thesis Reset
Summary Perrigo was our biggest loser in 2025 at -46%, and the pain continued into Q1. What was once viewed as a cyclical headwind now appears more structural, as the infant formula business has struggled to regain market share and shelf space. While we added to the position, it remains on the smaller side of our core holdings, balancing what has been a more challenging path than we initially expected with what we view as a business near its bottom. Read the full article on Seeking AlphaNarratiefupdate • Apr 22
PRGO: Future Upside Will Depend On Infant Nutrition Recovery Trajectory
Analysts have trimmed their price targets on Perrigo to a range of about $15 to $17, reflecting updated views on softer infant nutrition trends, along with ongoing share gains in private label and key branded products. Analyst Commentary Recent research on Perrigo centers on how well management can balance areas of weakness in infant nutrition with ongoing share gains in private label and key branded products, and how that balance feeds into valuation around the mid-teens price target range.Narratiefupdate • Apr 08
PRGO: Future Upside Will Depend On Infant Nutrition Recovery And Share Gains
Analysts have reduced Perrigo's average price target by $3, citing continued pressure in the infant nutrition business, while other product lines show steadier performance and share gains. Analyst Commentary Recent commentary on Perrigo focuses on how management is handling pressure in infant nutrition while trying to keep the rest of the portfolio on track.
Narratiefupdate • Mar 25
PRGO: Infant Nutrition Headwinds Will Shape Future Earnings Power Narrative
Analysts have reduced the Perrigo price target to $15 from $27, reflecting updated assumptions for lower revenue growth, slimmer profit margins, a higher discount rate, and a higher future P/E multiple in their models. Analyst Commentary Across recent research updates, bearish analysts have taken a more cautious stance on Perrigo, concentrating on where execution and growth trends may not fully support prior valuation assumptions.Narratiefupdate • Mar 09
PRGO: Future Upside Will Hinge On Infant Nutrition Business Stabilization
Perrigo's updated analyst price target has been reduced from $21 to $17, as analysts factor in softer revenue expectations, lower projected profit margins, a higher discount rate, and recent Street research pointing to pressure in the infant nutrition business even as other segments hold up. Analyst Commentary Recent Street research on Perrigo points to a mixed setup, with price targets moving lower but differing views on how much of the pressure is already reflected in valuation.
Narratiefupdate • Feb 23
PRGO: Index Reclassification And Modeling Shifts Will Shape Future Upside Potential
Narrative Update on Perrigo Analysts kept their Perrigo fair value estimate steady at $28.00 while slightly adjusting inputs such as discount rate, revenue growth, profit margin, and future P/E. This reflects updated modeling rather than a major shift in their outlook.Narratiefupdate • Feb 08
PRGO: Index Reclassification And Lawsuit Risk Will Shape Future Upside Potential
Analysts have reduced their price target on Perrigo from US$40 to US$28, citing updated assumptions that reflect a higher discount rate, more muted revenue growth and profit margins, and a modestly higher future P/E multiple in line with broader sector target resets. Analyst Commentary Bullish analysts looking at companies with adjusted price targets are generally focusing on how revised assumptions around discount rates, growth, and margins flow through to valuation, rather than short term share price moves.Narratiefupdate • Jan 25
PRGO: Future Upside Will Depend On Infant Nutrition Business Review Execution
Narrative Update The analyst price target on Perrigo has been reduced by $12 to $20. Analysts are factoring in slower infant formula recovery, competitive pressure, and less certain over-the-counter trends, which are contributing to slightly weaker growth, margins, and a higher assumed future P/E multiple.Narratiefupdate • Jan 11
PRGO: Future Upside Will Hinge On Infant Nutrition Business Review Execution
Narrative Update: Perrigo Analysts have cut their price target on Perrigo to $20 from $32, reflecting reduced revenue growth and profit margin expectations, slower progress in the infant formula and over the counter businesses, and a modest adjustment to the assumed future P/E multiple. Analyst Commentary The recent reset in expectations on Perrigo centers on slower progress in key growth areas and a reassessment of what investors are willing to pay for the shares, reflected in the lower price target to $20 from $32 and a downgrade to Neutral by JPMorgan following the Q3 report.Narratiefupdate • Dec 27
PRGO: Future Upside Will Depend On Infant Formula Recovery Execution
Analysts have modestly reduced their price target on Perrigo to $21.00 from $21.50, citing increased near term business uncertainty, a slower than expected recovery in infant formula amid heightened competition, and mixed over the counter market trends. Analyst Commentary Recent commentary from JPMorgan underscores a shift to a more cautious stance on Perrigo, with the firm cutting its rating to Neutral and trimming its price target to $20 from $32 following the Q3 report.Narratiefupdate • Dec 13
PRGO: Future Upside Will Depend On Infant Formula Business Resolution
Analysts have lowered their price target on Perrigo to $20 from $32 as they factor in slower than expected recovery in the infant formula segment, rising competitive pressures, and increased uncertainty around over the counter market trends over the next year. Analyst Commentary Bullish analysts highlight that Perrigo's core franchise remains intact despite near term turbulence.Narratiefupdate • Nov 28
PRGO: Future Recovery Will Depend On Resolution Of Infant Formula Challenges
Analysts have lowered their price target for Perrigo from $32 to $20, citing increased uncertainty and a slower than expected recovery in the company's infant formula business as key factors behind the shift. Analyst Commentary Analysts have provided mixed commentary on Perrigo following its recent quarterly report, reflecting both opportunities and challenges that could influence the company's valuation and long-term growth prospects.Narratiefupdate • Nov 14
PRGO: Recovery Momentum Will Improve As Infant Formula Pressures Ease
Analysts have lowered their price target for Perrigo from $32.50 to $21.50 per share. They cite increased uncertainty around recovery in the infant formula business and challenging trends in the over-the-counter market.Analyseartikel • Nov 07
Perrigo Company plc (NYSE:PRGO) Not Doing Enough For Some Investors As Its Shares Slump 31%
Perrigo Company plc ( NYSE:PRGO ) shareholders that were waiting for something to happen have been dealt a blow with a...Narratiefupdate • Oct 31
PRGO: Profit Margins And Operational Strength Will Support Long-Term Upside Potential
Analysts have lowered their price target for Perrigo from $33.50 to $32.50. They cite modestly slower projected revenue growth, although profit margins and discount rate assumptions remain stable.Narratiefupdate • Oct 16
Store-brand Adoption And Self-Care Trends Will Expand The OTC Market
Narrative Update on Perrigo Price Target Analysts have lowered their price target for Perrigo from $34.25 to $33.50. They cite minor shifts in projected revenue growth and discount rates as key inputs for this downward revision.Narratiefupdate • Aug 08
Store-brand Adoption And Self-Care Trends Will Expand The OTC Market
With both Perrigo’s discount rate and future P/E multiple remaining effectively unchanged, analysts have held their consensus price target steady at $34.25. What's in the News Perrigo reaffirmed fiscal year 2025 earnings guidance, expecting reported net sales growth of 0% to 3% and organic net sales growth of 1.5% to 4.5%.Analyseartikel • Jun 25
Insufficient Growth At Perrigo Company plc (NYSE:PRGO) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 0.8x Perrigo Company plc ( NYSE:PRGO ) may be sending very bullish signals at...Nieuw narratief • May 11
Americas Awards And Supply Chain Savings Will Fuel Future Performance
Strategic investments in OTC brands and enhanced supply chain efficiencies are poised to improve Perrigo's operating margins and revenue growth.Analyseartikel • Apr 28
Is Perrigo (NYSE:PRGO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 24
Perrigo: Opill Shows Where The Company Wants To Be
Summary Perrigo's transformation from a low-margin generics manufacturer to a branded consumer self-care company hinges on the success of products like Opill and Mederma. Despite short-term revenue declines, Perrigo's margin expansion and cost-saving initiatives show promise for long-term growth and strategic focus. The company's financial health is under pressure, with high leverage and volatile infant formula business posing significant risks. PRGO is a potential buy for long-term investors willing to accept the risks and rewards of a company in transition. Read the full article on Seeking AlphaAnalyseartikel • Feb 28
Perrigo's (NYSE:PRGO) Shareholders Will Receive A Bigger Dividend Than Last Year
Perrigo Company plc's ( NYSE:PRGO ) periodic dividend will be increasing on the 25th of March to $0.29, with investors...Analyseartikel • Feb 06
Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 0.8x Perrigo Company plc ( NYSE:PRGO ) may be sending bullish signals at the...Seeking Alpha • Jan 28
Perrigo Paves The Way For Recovery With Margin Focus
Summary Perrigo is a focused OTC consumer healthcare player, slimming down operations and enhancing margins under new management, with a 4.6% dividend yield. Despite short-term pressures from a weak cold-and-flu season and infant formula production issues, PRGO is positioned for recovery and growth by 2026. The company is exploring new markets with a 'disruptive growth' team, focusing on women's health and GLP-1 side effect relief, aiming for mid-single-digit growth. PRGO's Project Energize targets $150 million in annual savings by 2026, with significant debt management and a stable dividend, making it a solid dividend stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 20
Perrigo: A Consumer Health Company Close To An Inflection Point
Summary Perrigo's strategic focus on consumer self-care products and divestment of non-core assets positions it for strong growth and higher margins. The company's extensive product range and regulatory expertise provide a competitive advantage, especially in the OTC pharmaceutical market. Recent management changes and operational improvements, including cost-cutting initiatives and supply chain optimization, are expected to drive significant earnings growth. Perrigo's launch of Opill, the first OTC birth control pill, and the turnaround of its infant formula business, present substantial future growth opportunities. Read the full article on Seeking AlphaAnalyseartikel • Dec 06
Is Perrigo (NYSE:PRGO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Nov 19
Perrigo Company: Great Combination Of Future Growth With A Low Valuation
Summary Perrigo's long-term growth is driven by strategic initiatives like Project Energize, aiming for $140-$170 million in annualized savings by 2026. The company's reinvestments in leadership and IT, adding 200 years of consumer experience, are crucial for sustainable growth. Perrigo's supply chain reinvention program has already achieved $72 million in gross savings, enhancing cash flow and operational efficiency. The stock's valuation remains attractive, as technical indicators point to a rising stock price, making it a compelling investment opportunity. Read the full article on Seeking AlphaAnalyseartikel • Nov 07
Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276
The board of Perrigo Company plc ( NYSE:PRGO ) has announced that it will pay a dividend of $0.276 per share on the...Analyseartikel • Oct 18
Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 0.8x Perrigo Company plc ( NYSE:PRGO ) may be sending very bullish signals at...Analyseartikel • Aug 21
Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276
The board of Perrigo Company plc ( NYSE:PRGO ) has announced that it will pay a dividend of $0.276 per share on the...Seeking Alpha • Aug 16
The Play On Perrigo
Summary Perrigo Company plc's shares recently hit a 15-year low due to issues at infant formula facilities, but efficiency initiatives and Opill launch show promise. The company is focused on becoming more efficient through SKU prioritization and cost-saving initiatives, despite challenges with infant formula facilities. Perrigo's Q2 results were mixed, with reduced sales guidance for FY2024, but analysts remain bullish on the stock, expecting growth in earnings and revenue in FY2025. An updated analysis around Perrigo follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Aug 07
Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276
Perrigo Company plc ( NYSE:PRGO ) will pay a dividend of $0.276 on the 17th of September. Based on this payment, the...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 28 2026 | n/a | n/a | -US$2b |
| Dec 31 2025 | US$9m | US$1m | -US$1b |
| Sep 27 2025 | n/a | n/a | -US$29m |
| Jun 28 2025 | n/a | n/a | -US$59m |
| Mar 29 2025 | n/a | n/a | -US$165m |
| Dec 31 2024 | US$8m | US$1m | -US$161m |
| Sep 28 2024 | n/a | n/a | -US$147m |
| Jun 29 2024 | n/a | n/a | -US$114m |
| Mar 30 2024 | n/a | n/a | US$800k |
| Dec 31 2023 | US$7m | US$605k | -US$4m |
Compensatie versus markt: De totale vergoeding ($USD 9.04M ) Patrick } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.48M ).
Compensatie versus inkomsten: De vergoeding van Patrick is gestegen terwijl het bedrijf verliesgevend is.
CEO
Patrick Lockwood-Taylor (56 yo)
2.9yrs
Tenure
US$9,042,603
Compensatie
Mr. Patrick Lockwood-Taylor has been President, Chief Executive Officer and Director at Perrigo Company plc since June 30, 2023. He was Regional President and Head North American Consumer Health Business a...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 2.9yrs | US$9.04m | 0.080% $ 1.2m | |
| Executive VP & CFO | 4yrs | US$3.67m | 0.056% $ 867.8k | |
| EVP & Chief Scientific Officer | 1.3yrs | US$2.99m | 0.0020% $ 31.0k | |
| Executive VP | 1.6yrs | US$2.90m | 0.00072% $ 11.1k | |
| Executive VP & Chief Commercial Officer | 1.8yrs | US$3.15m | 0.0038% $ 58.1k | |
| Vice President of Global Investor Relations | less than a year | geen gegevens | geen gegevens | |
| Chief Human Resources Officer & Executive VP | 7.2yrs | geen gegevens | 0.035% $ 546.0k | |
| EVP and Chief Brand & Digital Officer | 1.8yrs | geen gegevens | 0.0036% $ 54.8k | |
| Executive Vice President of Product Supply | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Treasurer | no data | geen gegevens | geen gegevens |
1.8yrs
Gemiddelde duur
48.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PRGO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 2.9yrs | US$9.04m | 0.080% $ 1.2m | |
| Independent Director | 9.3yrs | US$311.62k | 0.0076% $ 117.8k | |
| Independent Director | 11.5yrs | US$314.95k | 0.026% $ 397.6k | |
| Independent Director | 1.3yrs | US$298.14k | 0.0039% $ 60.2k | |
| Independent Director | 9.3yrs | US$294.13k | 0.032% $ 501.7k | |
| Independent Director | 3.8yrs | US$294.13k | 0.012% $ 182.5k | |
| Independent Chairman of the Board | 5.4yrs | US$472.39k | 0.020% $ 309.3k | |
| Independent Director | 2.5yrs | US$302.13k | 0.0086% $ 132.0k | |
| Independent Director | 9.5yrs | US$294.13k | 0.055% $ 847.8k | |
| Independent Director | 9yrs | US$314.79k | 0.020% $ 308.4k | |
| Independent Director | 1yr | US$265.05k | 0.0027% $ 42.3k |
5.4yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PRGO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 17:02 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/28 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Perrigo Company plc wordt gevolgd door 32 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Douglas Tsao | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |